Samir Pancholy, MD
Interventional Cardiology · Clarks Summit, PANPI 1609846674
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,840 of the $81,054 with a category attached, or 83.7%. 23 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 45.3% of the total. Reporting peaked in 2019 at $23,497 and has fallen 78.7% since, to $5,013 in 2025.
Across 221 payments — averaging $366.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$37K
- E.r. Squibb & Sons, L.L.C.$33K
- Pfizer$3K
- Medtronic$2K
- Siemens Medical Solutions USA, Inc.$2K
- Terumo Medical Corporation$2K
- plus $3K from 17 others
What the payments were for
- Consulting fees$2,3003%
- Speaking & faculty fees$67,84084%
- Travel & lodging$4,6196%
- Food & beverage$6,2098%
- Education$860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 54 | $36,739 |
| E.r. Squibb & Sons, L.L.C. | 23 | $32,620 |
| Pfizer | 9 | $2,668 |
| Medtronic(2 entities) | 15 | $2,120 |
| Siemens Medical Solutions USA, Inc. | 6 | $1,977 |
| Terumo Medical Corporation | 1 | $1,700 |
| Boston Scientific | 42 | $894 |
| Eisai Inc. | 6 | $658 |
| Novartis | 31 | $487 |
| Actelion Pharmaceuticals US, Inc. | 3 | $218 |
| Corindus Inc. | 1 | $148 |
| Amgen | 2 | $143 |
| Abbott | 8 | $139 |
| Abiomed | 3 | $129 |
| Shockwave Medical, Inc | 4 | $90 |
| Philips North America LLC | 3 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $60 |
| Novo Nordisk | 1 | $50 |
| AstraZeneca | 2 | $48 |
| Cardinal Health 200 LLC | 1 | $35 |
| Biotronik Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $18 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$35,250
- ELIQUIS$34,356
- CorPath GRX$1,946
- Optitorque$1,700
- Heartrail$1,700
- TR Band$1,700
- Glidesheath$1,700
- Resolute$1,600
- Leqembi$249
- Fycompa$223
- UPTRAVI$125
- OPSUMIT$125
- SYMPLICITY G3$121
- Watchman$112
- Impella$100
How this compares
$81,054 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 431 | $368,030 |
| EntrestoSacubitril/Valsartan | 209 | $231,347 |
| XareltoRivaroxaban | 66 | $64,142 |
| JardianceEmpagliflozin | 32 | $46,781 |
| BrilintaTicagrelor | 32 | $17,966 |
| Metoprolol Succinate | 515 | $10,474 |
| Repatha SyringeEvolocumab | 13 | $3,462 |
| Losartan Potassium | 189 | $3,126 |
| Atorvastatin Calcium | 258 | $2,974 |
| ClopidogrelClopidogrel Bisulfate | 153 | $2,140 |
| Amlodipine Besylate | 229 | $1,886 |
| Metoprolol Tartrate | 159 | $1,788 |
| Midodrine Hcl | 17 | $1,648 |
| Labetalol Hcl | 49 | $1,544 |
| Flecainide Acetate | 24 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,668 | $368,030431 claims |
| NovartisEntresto | $487 | $231,347209 claims |
| Johnson & JohnsonXarelto | $18 | $64,14266 claims |
| AstraZenecaBrilinta | $48 | $17,96632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Clarks Summit
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- James HarveyChambersburg$442K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.